EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Advances in Gene Therapy for Sickle Cell Disease: From Preclinical Innovations to Clinical Implementation and Access Challenges

Henna Butt, Mamatha Mandava, David Jacobsohn iD

The CRISPR Journal · 2025

DOI: 10.1089/crispr.2024.0101 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The CRISPR Journal, 2025. Verfasst von Henna Butt und 2 weiteren Autor:innen. Beteiligte Einrichtung: Cancer and Blood Disorders Center, Children's National Hospital, Washington, District of Columbia, USA. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Genetic Therapy, Gene Editing. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 74 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sickle cell disease (SCD) is a hereditary blood disorder caused by a specific mutation in the β-globin gene, leading to the production of hemoglobin S, which deforms red blood cells, causing occlusion in small blood vessels. This results in pain, anemia, organ damage, infections, and increased stroke risk. Treatment options, including disease-modifying therapies and curative hematopoietic stem cell transplants, have limited accessibility. Recently, autologous gene therapy has emerged as a promising curative option, particularly for SCD. Gene editing techniques such as CRISPR, base editing, and prime editing offer potential to correct this mutation. In this review, we discuss recent preclinical studies and clinical trials of gene and cell therapies, focusing on the progress of FDA-approved treatments like Lyfgenia and Casgevy. We also examine the many challenges, including accessibility, safety, and long-term efficacy, which continue to shape the future of SCD gene therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellGenetic TherapyGene EditingHumansCRISPR-Cas SystemsAnimalsbeta-GlobinsMutation

Substanzen

beta-Globins

Autor:innen und Institutionen

  • Cancer and Blood Disorders Center, Children's National Hospital, Washington, District of Columbia, USA.
  • George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA.

ORCID-Profile: David Jacobsohn

Zitieren

APA

Butt, H., Mandava, M., & Jacobsohn, D. (2025). Advances in Gene Therapy for Sickle Cell Disease: From Preclinical Innovations to Clinical Implementation and Access Challenges. The CRISPR Journal. https://doi.org/10.1089/crispr.2024.0101

Vancouver

Butt H, Mandava M, Jacobsohn D. Advances in Gene Therapy for Sickle Cell Disease: From Preclinical Innovations to Clinical Implementation and Access Challenges. The CRISPR Journal. 2025. doi:10.1089/crispr.2024.0101

BibTeX
@article{Butt2025,
  author = {Butt, Henna and Mandava, Mamatha and Jacobsohn, David},
  title = {Advances in Gene Therapy for Sickle Cell Disease: From Preclinical Innovations to Clinical Implementation and Access Challenges},
  journal = {The CRISPR Journal},
  year = {2025},
  doi = {10.1089/crispr.2024.0101}
}
Kostenlos starten →